Q32 Bio Inc.

NasdaqGM:QTTB Stock Report

Market Cap: US$37.9m

Q32 Bio Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jodie Morrison

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage48.8%
CEO tenureless than a year
CEO ownershipn/a
Management average tenure1.2yrs
Board average tenureless than a year

Recent management updates

Recent updates

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

Aug 29

CEO Compensation Analysis

How has Jodie Morrison's remuneration changed compared to Q32 Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$57m

Mar 31 2024n/an/a

-US$46m

Dec 31 2023US$1mUS$525k

-US$54m

Sep 30 2023n/an/a

-US$36m

Dec 31 2022US$2mUS$120k

-US$43m

Compensation vs Market: Jodie's total compensation ($USD1.08M) is above average for companies of similar size in the US market ($USD649.63K).

Compensation vs Earnings: Jodie's compensation has been consistent with company performance over the past year.

CEO

Jodie Morrison (48 yo)

less than a year

Tenure

US$1,075,907

Compensation

Ms. Jodie Pope Morrison is Director of Verve Therapeutics, Inc. from June 2024. Ms. Jodie Pope Morrison serves as Chief Executive Officer and Director of Q32 Bio Inc. since March 2024. Ms. Morrison previou...

Leadership Team

NamePositionTenureCompensationOwnership
Jodie Morrison
CEO & Directorless than a yearUS$1.08mno data
Shelia Violette
Co-founder7.3yrsUS$716.22k0.49%
$ 187.1k
Jason Campagna
Chief Medical Officerless than a yearUS$680.93k0%
$ 0
Lee Kalowski
CFO & Presidentless than a yearno data0%
$ 0
Saul Fink
Chief Technology Officer1.2yrsno datano data
David Appugliese
Senior VP & Head of People2.3yrsno datano data
Maria Marzilli
Executive Vice President of Corporate Strategy & Program Operations1.9yrsno datano data
Kathryn Golden
Head of Chemistryno datano datano data

1.2yrs

Average Tenure

52.5yo

Average Age

Experienced Management: QTTB's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jodie Morrison
CEO & Directorless than a yearUS$1.08mno data
Kathleen LaPorte
Independent Directorless than a yearUS$40.00k0.045%
$ 16.9k
Mary Thistle
Independent Directorless than a yearno data0%
$ 0
Brian Kotzin
Scientific Advisorno datano datano data
John Atkinson
Scientific Advisorno datano datano data
David Grayzel
Independent Directorless than a yearno datano data
Isaac Manke
Independent Directorless than a yearno datano data
Mark Iwicki
Independent Directorless than a yearUS$50.00k0%
$ 0
Sven Lundberg
Independent Directorless than a yearUS$40.00k0.0098%
$ 3.7k
Diyong Xu
Independent Directorless than a yearno datano data
Michael Holers
Scientific Advisorno datano datano data
Simon Read
Scientific Advisor2.9yrsno datano data

0.8yrs

Average Tenure

57yo

Average Age

Experienced Board: QTTB's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 23:52
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Q32 Bio Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBMO Capital Markets Equity Research
Thomas SmithLeerink Partners LLC
Jay OlsonOppenheimer & Co. Inc.